---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-148865"
form_type: "8-K"
ticker: "IVVD"
cik: "0001832038"
company_name: "Invivyd, Inc."
filed_at: "2026-04-09T23:59:59+00:00"
generated_at: "2026-05-15T06:48:43.163980+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Invivyd announces Phase 3 DECLARATION upsizing; new measles antibody VMS063

## Summary
- DECLARATION Phase 3 COVID-19 prophylaxis study upsized by ~500 subjects; top-line results now expected in Q3 2026, shifted from mid-2026.
- Pooled, blinded COVID-19 events at 1,500 subjects (Day 45) already support statistical power for high end of anticipated VYD2311 efficacy.
- FDA alignment on initial Pediatric Study Plan for VYD2311 (DRUMMER study) for children aged 0-11 years, contingent on DECLARATION success.
- New measles mAb candidate VMS063 targets F protein, shows potent in vitro neutralization (picogram/mL IC50s) across B3, D8, Edmonston lineages; IND-enablement started.
- VMS063 is half-life extended, planned for treatment and prophylaxis in measles; U.S. measles incidence in 2026 on track to exceed 2025.

## SEC filing metadata
- accession: 0001193125-26-148865
- form_type: 8-K
- ticker: IVVD
- cik: 0001832038
- company_name: Invivyd, Inc.
- filed_at: 2026-04-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832038/000119312526148865/0001193125-26-148865-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832038/000119312526148865/d147019d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-148865
- JSON: https://secwatch.observer/filing/0001193125-26-148865.json
- Plain text: https://secwatch.observer/filing/0001193125-26-148865.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.